Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Cash & Equivalents (2016 - 2025)

Vistagen Therapeutics' Cash & Equivalents history spans 13 years, with the latest figure at $47.4 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 36.6% year-over-year to $47.4 million; the TTM value through Dec 2025 reached $47.4 million, down 36.6%, while the annual FY2025 figure was $67.1 million, 43.67% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $47.4 million at Vistagen Therapeutics, down from $62.8 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $126.6 million in Q4 2023 and bottomed at $9.6 million in Q2 2023.
  • The 4-year median for Cash & Equivalents is $83.7 million (2021), against an average of $77.3 million.
  • The largest annual shift saw Cash & Equivalents soared 7508.91% in 2021 before it crashed 52.4% in 2025.
  • A 4-year view of Cash & Equivalents shows it stood at $83.7 million in 2021, then soared by 51.21% to $126.6 million in 2023, then tumbled by 40.96% to $74.7 million in 2024, then tumbled by 36.6% to $47.4 million in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Cash & Equivalents are $47.4 million (Q4 2025), $62.8 million (Q3 2025), and $49.0 million (Q2 2025).